|
|
|
13.11.26 - 17:30
|
Merck KGaA-Aktie: Halbleiter glänzen, US-Umsatz schmilzt (Sharedeals)
|
|
|
Merck KGaA hat die Jahresprognose zum dritten Mal angehoben, getragen von Chipmaterialien und Process Solutions. Gleichzeitig bricht der US-Umsatz von Mavenclad weg, und die Bio-Techne-Übernahme kostet Spielraum. Ich habe mir angeschaut, was das für 2027 und die seit Jahren eingefrorene Dividende bedeutet.
The post Merck KGaA-Aktie: Halbleiter glänzen, US-Umsatz schmilzt first appeared on sharedeals.de....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12.11.26 - 14:30
|
Merck KGaA (MKKGY) Lags Q3 Earnings Estimates (Zacks)
|
|
|
Merck KGaA (MKKGY) delivered earnings and revenue surprises of -52.00% and +5.32%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?...
|
|
|
12.11.26 - 14:03
|
Silence Therapeutics Highlights Recent Business Achievements and Reports Third Quarter 2026 Financial Results (Business Wire)
|
|
|
LONDON--(BUSINESS WIRE)--$SLN #SenseofSilence--Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the third quarter ended September 30, 2026, and provided an update on other recent business achievements.
Recent Business Highlights
On August 10, 2026, Silence reported positive topline results from its Phase 2 SANRECO trial of divesiran, an investigational siRNA therapy silencing TMPRSS6, in polycythemia vera, supporting a potentially best-in-class profile with once-every-three-month dosing.
SANRECO Phase 2 results have been accepted for oral presentation at the upcoming American Society of Hematology (ASH) 2026 Annual Meeting, being held December 12-15, 2026 in New Orleans, LA. You can find the presentation details here.
On October 19, 2026, Silence announced (press release) that it has entered into a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany. The transaction ...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|